Chimeric: Media Thread, page-669

Bio M&A going strong. Biopharma M&A activity increased more than 100% in the first quarter of 2024 with 13 transactions in Q1 2024 compared to 6 transactions in Q1 2023

https://www.leerink.com/articles/analyzing-healthcare-ma-trends-q1-2024-insights/

Biopharmaceuticals remained the most active sub-sector of Healthcare and represented 34% of deal value and 45% of deal volume in Q1 2024 (vs. 63% of deal value and 21% of deal volume in Q1 2023).

Oncology was the most active therapeutic area, with 7 transactions totaling $9B in deal value.

1Q 2024 BIOPHARMA | M&A ACTIVITY

Biopharma M&A activity increased more than 100% in the first quarter of 2024 with 13 transactions in Q1 2024 compared to 6 transactions in Q1 2023





Here's a couple more.

Vertex Pharmaceuticals is buying Alpine Immune Sciences for $4.9 billion

https://www.fiercebiotech.com/biotech/vertex-pays-49-billion-hike-alpines-immunology-trail

Takeda inks sweet $1.2B-plus deal with Kumquat for immuno-oncology program

https://www.fiercebiotech.com/biotech/takeda-inks-sweet-12b-deal-kumquat-immuno-oncology-program

This one is really interesting.

Genmab acquires privately owned biotech ProfoundBio for $1.8 billion in cash.

So ProfoundBio has 2 lead candidates PRO1184 and PRO1160. Both were set up as a phase 1/2 trial and neither had completed their estimated primary completion at the time of the buyout. PRO1160 estimated primary completion date was 30/4/2024 and PR01184 January 2025.

https://www.biospace.com/article/genmab-leans-into-hot-adc-space-with-1-8b-profoundbio-acquisition-/
https://www.profoundbio.com/Clinical-Trials
https://clinicaltrials.gov/study/NCT05579366
https://classic.clinicaltrials.gov/ct2/show/NCT05721222


So CHM 2101 trial has been set up the same, phase 1/2. Same amount of patients and same timeframe as PRO1184. It will not surprise me in the slightest if we get bought out in the next couple of years.

Right time and place.